News Home

Press Releases

Quarterly SEC Filings

Supply Update

Subscribe






2012 | 2011| 2010 | 2009 | 2008

11/14/11 Lantheus Medical Imaging to Host Third Quarter 2011 Conference Call on November 21, 2011 at 4:00 p.m. Eastern Time
10/27/11 Lantheus Medical Imaging Announces Labeling Changes for DEFINITY®
10/24/11 Lantheus Medical Imaging Awarded Three-Year Supplier Agreements with the Premier Healthcare Alliance for Ultrasound Contrast Agent DEFINITY® andMagnetic Resonance Angiography Imaging Agent ABLAVAR®
10/24/11 Lantheus Medical Imaging Awarded Three-Year Supplier Agreement with the Premier Healthcare Alliance for Radiopharmaceutical Products
09/28/11 Lantheus Medical Imaging Announces Promotion Of Cyrille Villeneuve To Chief Commercial Officer And Dana Washburn, M.D. To Chief Medical Officer
08/16/11 Lantheus Medical Imaging to Host Second Quarter 2011 Conference Call on August 23, 2011 at 4:00 p.m. Eastern Time
07/27/11 Lantheus Medical Imaging Announces Management Change
07/26/11 Lantheus Medical Imaging Announces Promotion Of Jeffrey Young To Vice President, Finance
06/30/11 Lantheus Medical Imaging Initiates Phase 3 Clinical Trial of Flurpiridaz F 18 for the Detection of Coronary Artery Disease
06/02/11 Lantheus Medical Imaging to Present at Jefferies 2011 Global Healthcare Conference
06/01/11 Lantheus Medical Imaging to Present Data on Novel PET Cardiac and Heart Failure Imaging Agents at SNM 58th Annual Meeting
05/18/11 Lantheus Medical Imaging to Host First Quarter 2011 Conference Call on May 23, 2011 at 4:00 p.m. Eastern Time
05/17/11 Lantheus Medical Imaging Presents Phase 2 Study Results of PET Myocardial Perfusion Imaging with Flurpiridaz F 18 at ICNC10
05/13/11 Lantheus Medical Imaging to Present Phase 2 Data of PET Myocardial Perfusion Imaging with Flurpiridaz F 18 at the International Conference of Non-Invasive Cardiovascular Imaging
05/10/11 Lantheus Medical Imaging Announces Completion of Exchange Offer for its 9.750% Senior Notes Due 2017
05/03/11 Lantheus Medical Imaging Presents Promising Results of Latest Safety Studies on DEFINITY® to FDA Advisory Committees
04/11/11 Lantheus Medical Imaging Commences Exchange Offer
03/21/11 Lantheus Medical Imaging Completes Private Offering of $150 Million of 9.750% Senior Notes Due 2017
03/16/11 Lantheus Medical Imaging Announces Expiration of Consent Solicitation and Receipt of Requisite Consents
03/16/11 Lantheus Medical Imaging Announces Proposed Private Offering of $150 Million of Senior Unsecured Notes
03/11/11 Lantheus Medical Imaging Receives Special Protocol Assessment Approval from FDA for Phase 3 Trial of Flurpiridaz F-18 for the Diagnosis of Coronary Artery Disease
03/04/11 Lantheus Medical Imaging Commences Consent Solicitation
02/03/11 Lantheus Medical Imaging Announces Completion of Exchange Offer for its 9.750% Senior Notes Due 2017
01/21/11 Lantheus Medical Imaging Announces New National Contract with Novation for ABLAVAR® and DEFINITY®
01/18/11 Lantheus Medical Imaging Announces Promotion Of Robert Gaffey To Chief Financial Officer
01/05/11 Lantheus Medical Imaging Extends Molybdenum-99 Contract with Nordion

© 2012 Lantheus Medical Imaging, Inc.

Use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.
ABLAVAR, Cardiolite, DEFINITY, TechneLite and the corporate logo display are registered trademarks of Lantheus Medical Imaging, Inc.
Any unlicensed use of these trademarks is expressly prohibited under the U.S. Trademark Act.
Intended for U.S. Residents Only